CapitalBio Technology

What CapitalBio Technology does

CapitalBio Technology is a privately held Chinese life sciences company that develops, manufactures, and commercializes biochip-based in vitro diagnostics (IVD) solutions for genetic research and clinical testing. Founded in August 2012 as the industrialized platform of CapitalBio Corporation and the Biochip Beijing National Engineering Research Center, the company operates as one of the core enterprises of Tsinghua University in the life and health field, with a headquarters in Beijing's Yizhuang Biomedical Park and additional production, R&D, and marketing centers in Shanghai, Chongqing, Chengdu, Dongguan, Hong Kong, and San Diego.

The company's portfolio rests on five proprietary platform technologies — microarray (LuxScan scanners, slide washer, hybridization station), microfluidic (RTisochip-A/W isothermal amplification analyzers, integrated SARS-CoV-2 and mobile laboratory systems), semiconductor sequencing (BioelectronSeq 4000 sequencer), the IMAP microfluidic array platform for SNP/InDel detection, and real-time PCR systems (DxLab-32A, FS-3200) — supported by proprietary consumables (CalSlide-III calibration slides, hybridization boxes) and a broad menu of health solutions covering infectious disease control, maternal and child healthcare, anti-cancer targeted therapy guidance, pharmacogenomics, and precision healthcare management. Sequencing and research services (microbiome, single-cell, transcriptome, microarray gene chip, Agena MassARRAY, and biochip design/fabrication) complete the offering.

CapitalBiotech runs a B2B, sales-led go-to-market with a global direct sales team reachable via [email protected] and phone, supported by a professional website, educational content, downloadable brochures, and international trade show participation. Pricing is not publicly disclosed and is handled via enterprise inquiry with multi-year contracts. Customers span hospitals, clinical diagnostic laboratories, research institutions and academia, and applied markets (forensics, food safety, agriculture), with named collaborations including Beijing Tiantan Hospital, the Chinese Academy of Sciences' Beijing Institute of Genomics, Southeast University School of Medicine, and Nanjing Chest Hospital. Leadership includes President Dr. Sun Yimin (per the most recent 2025 disclosure) and Assistant President Dr. Li Yanze.

Name

CapitalBio Technology

Legal name

CapitalBiotech Co., Ltd.

Website

https://capitalbiotechnology.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

501–1,000 employees

Short description

CapitalBio Technology is a privately held Beijing-based life sciences company that develops and sells biochip-based in vitro diagnostics (IVD) platforms, instruments, consumables, and sequencing services to hospitals, clinical laboratories, and research institutions in China and internationally.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI)

akta.pro secondary industries

Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF), Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)

Keywords

• In vitro diagnostics
• Biochip technology
• Molecular diagnostics
• Genetic testing instruments
• Clinical sequencing services

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Instruments and Equipment: Sale of life science instruments including microarray scanners, sequencers, PCR systems, microfluidic analyzers, and supporting equipment for genetic testing and diagnostics.
2. Consumables and Reagents: Sale of consumables including calibration slides, hybridization boxes, and diagnostic reagent kits for various genetic tests.
3. Health Solutions and Testing Services: Comprehensive health solutions including infectious disease testing, maternal and child healthcare, anti-cancer therapy guidance, pharmacogenomics, and precision healthcare management services.
4. Sequencing Services: Research services including microbiome sequencing, microarray gene chip analysis, biochip design and fabrication, single-cell sequencing, transcriptome sequencing, and Agena MassARRAY services.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

CapitalBiotech develops and manufactures biochip-based in vitro diagnostics (IVD) instruments, consumables, and clinical genetic testing solutions. The company sells proprietary platform technologies including microarray, microfluidic, semiconductor sequencing (BioelectronSeq 4000), and isothermal amplification systems, along with targeted health solutions for infectious disease, oncology, pharmacogenomics, prenatal screening, and forensic DNA testing. It also provides sequencing and biochip fabrication services to research institutions and clinical laboratories globally.

Product overview

CapitalBio Technology offers a comprehensive portfolio of biochip-based in vitro diagnostics (IVD) solutions for genetic research. The company provides multiple interconnected platform technologies including: Microfluidic Platform (combining microfluidic technology with isothermal amplification), Microarray Platform (with LuxScan scanners, Slide Washer, and Hybridization Station), Next Generation Sequencing Platforms (BioelectronSeq 4000 sequencer), IMAP Platform (for SNP/InDel detection), Smart Health Platform, Forensic Platform, and Real Time PCR systems. These core instrument platforms are supported by extensive consumables (CalSlide-III Calibration Slides, Hybridization Boxes) and a comprehensive suite of Health Solutions covering infectious disease control, maternal and child healthcare, anti-cancer therapy, pharmacogenomics, and precise healthcare management. The product portfolio includes targeted testing solutions for cancer (lung, colorectal, brain, breast, gastrointestinal, gynecologic, prostate, blood cancers), prenatal testing (NIPT, NIPT-Plus, PGS), pharmacogenomics, disease susceptibility genetic testing, metabolic testing, and infectious disease detection. Sequencing services complement the product portfolio with offerings in microbiome sequencing, single-cell sequencing, transcriptome sequencing, microarray analysis, and biochip fabrication.

Differentiator

Problem solved

Functional benefit

Brands

• RTisochip™: Isothermal Nucleic Acid Amplification Microfluidic Chip Analyzer product line
• LuxScan™
• BioelectronSeq
• IMAP
• Quick TargSeq
• DxLab
• NIPT
• PediCare

Products and services

• BioelectronSeq 4000 Sequencer Semiconductor sequencing platform with clinical testing kits and automated data analysis software for clinical laboratories.
• LuxScan 10K DNA Microarray Scanner Confocal microarray scanner for reading microarray chips and detecting fluorescence signals in genetic analysis.
• RTisochip-A Isothermal Nucleic Acid Amplification Microfluidic Chip Analyzer Microfluidic chip analyzer for rapid molecular diagnostics using isothermal nucleic acid amplification.
• RTisochip-W Isothermal Nucleic Acid Amplification Microfluidic Chip Analyzer Microfluidic chip analyzer variant for rapid molecular diagnostics using isothermal nucleic acid amplification.
• DxLab-32A Automated Nucleic Acid Purification and Real Time PCR System Integrated instrument combining automated nucleic acid purification with real-time PCR amplification for clinical diagnostics.
• FS-3200 Real-Time PCR System Real-time PCR system for nucleic acid detection and quantification in diagnostic applications.
• Quick TargSeq Fully Integrated Automatic On-site Quick DNA Test System Portable fully integrated DNA quick test system for on-site forensic analysis capable of delivering results in two hours or less.
• CalSlide-III Calibration Slide Calibration slide for calibrating microarray fluorescence scanners and comparing signal intensities.
• Hybridization Box Hybridization box holding 25mm x 75mm microarray slides in isolated environment to prevent evaporation during hybridization.
• Solutions for Infectious Disease Control Comprehensive molecular diagnostic solutions for respiratory pathogens, tuberculosis, HPV, bloodstream infections, and CNS/genitourinary infections.
• Solutions for Maternal and Child Healthcare Congenital disability prevention program including NIPT, NIPT-Plus, CNV-seq, PGS, and deafness-related gene mutation detection.
• Solutions for Anti-cancer Therapy Cancer diagnosis and treatment solutions combining genetic testing with targeted therapy for multiple cancer types.
• Solutions for Pharmacogenomics Pharmacogenomics testing solutions covering genes associated with drug metabolism, efficacy, and side effects for safer prescribing.
• Precise Diagnosis and Treatment for Brain Cancer Comprehensive brain tumor molecular testing covering molecular typing, diagnosis, prognosis, and drug treatment guidance.
• Targeted Medication Guidance for Lung Cancer Lung cancer targeted therapy guidance testing detecting SNV, InDel, CNV and gene rearrangement of 12 genes with FDA/NMPA drug coverage.
• Targeted Medication Guidance for Colorectal Cancer Colorectal cancer targeted drug guidance testing detecting 14 genes using tag-sequencing technology for targeted therapies including Cetuximab and Panitumumab.
• Fully Integrated Platform for COVID-19 Integrated platform combining microfluidic chips with nucleic acid extraction, nested isothermal amplification, and real-time fluorescence detection for COVID-19 testing.
• Single-Cell Sequencing Service Single-cell sequencing services including gene expression, transcriptome, immune repertoire, ATAC, CRISPR screening, and spatial multi-omics.
• Microbiome Sequencing Service Microbiome sequencing services including 16s/18s/ITS and shotgun metagenomics analysis.
• Transcriptome Sequencing Service Transcriptome sequencing services including mRNA, lncRNA, small RNA, and whole transcriptome sequencing.
• Agena MassARRAY Service MassARRAY-based SNP detection and methylation detection services.
• Biochip Design & Fabrication Service Custom biochip design and fabrication services including IMAP platform products.

Quantifiable outcome

• Forensic DNA test using microfluidic technology can be conducted in two hours or less
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• Chinese Embassy in KyrgyzstanflagshipGTM or Marketing Partner · 1 June 2025Dr. Sun Yimin, President of CapitalBiotech, along with Dr. Li Yanze, Assistant President, visited Kyrgyzstan to hold a working meeting with officials at the Chinese Embassy in Kyrgyzstan to promote the National Precision Medicine Center in Kyrgyzstan.
• Department of Neurosurgery, Beijing Tiantan HospitalcoreStrategic or Co-development Partner · 1 January 2025CapitalBiotech's Precise Diagnosis and Treatment for Brain Cancer panel was customized by Department of Neurosurgery, Beijing Tiantan Hospital, including 4 mutant types - 52 SNVs and Indels, 25 CNVs, 8 gene fusions, and 6 co-deletions/amplifications.
• Beijing Institute of Genomics, Chinese Academy of SciencescoreStrategic or Co-development Partner · 1 February 2022CapitalBiotech's single-cell platform supported the Beijing Institute of Genomics, Chinese Academy of Sciences, in publishing research on the heterogeneity of mesenchymal stem cells in the journal Genomics, Proteomics & Bioinformatics.
• Southeast University School of MedicinecoreStrategic or Co-development Partner · 1 January 2022CapitalBiotech cooperated with Southeast University School of Medicine and Nanjing Chest Hospital affiliated to Nanjing Medical University to publish research results discovering that anoikis resistance promotes lung fibroblast activation in the journal Cell & Bioscience. The study used 10x Visium spatial transcriptome sequencing technology provided by CapitalBiotech.
• Nanjing Chest Hospital affiliated to Nanjing Medical UniversitycoreStrategic or Co-development Partner · 1 January 2022Joint research collaboration on pulmonary fibrosis mechanisms using spatial transcriptomics and proteomics. The research was published in Cell & Bioscience journal.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• DaAn Gene (Kingmed Diagnostics): DaAn Gene is a major Chinese molecular diagnostics provider with broad infectious-disease, reproductive-health, and oncology reagent menus. It competes head-on with CapitalBiotech in clinical PCR and microarray-based diagnostics across Chinese hospital systems.
• Sansure Biotech: Sansure is a Chinese molecular diagnostics company specializing in nucleic acid diagnostic kits for infectious disease, oncology, and prenatal testing. It directly competes with CapitalBiotech's PCR, isothermal amplification, and infectious-disease detection reagent lines in Chinese hospitals and public health labs.
• Autobio Diagnostics: Autobio is a leading Chinese IVD company offering immunoassay, microbiology, and molecular diagnostics products. It is a comparable peer given its scale, Chinese hospital channel, and overlapping clinical diagnostic and infectious-disease offerings relative to CapitalBiotech.
• BGI Genomics: BGI Genomics is a Chinese genomics and IVD leader offering NIPT, oncology panels, and sequencing services. It is the closest direct competitor to CapitalBiotech in microarray/NGS-based clinical diagnostics and sequencing services, particularly in China and emerging markets.

Broad incumbents

• Roche Diagnostics: Roche Diagnostics is the global leader in clinical IVD, including molecular diagnostics, sequencing, and immunoassays. It competes broadly with CapitalBiotech's clinical microarray, NGS, and infectious-disease reagent menus and serves as a benchmark for clinical evidence and regulatory depth.
• Illumina: Illumina is the dominant global NGS platform provider with a deep sequencing instruments and reagents franchise. Its clinical sequencing products (e.g., TruSight Oncology) compete directly with CapitalBiotech's BioelectronSeq 4000-based oncology panels and NIPT workflows.
• Qiagen: Qiagen is a global molecular diagnostics and sample-preparation company with broad infectious-disease, oncology, and forensic offerings. It is comparable to CapitalBiotech given its overlap in PCR, sample-prep reagents, and forensic DNA testing workflows.
• Thermo Fisher Scientific: Thermo Fisher provides life-sciences instruments, reagents, and clinical diagnostics across sequencing, microarray, and PCR. It is comparable to CapitalBiotech on the instrument and consumable side of the business and represents a key competitor in NGS and microarray platforms.
• Mindray Medical: Mindray is a dominant Chinese medical device and IVD company spanning patient monitoring, in-vitro diagnostics, and medical imaging. It is a broad incumbent comparable to CapitalBiotech because of its size, Chinese distribution, and overlapping IVD reagent and instrument portfolios.

Emerging players

• Genetron Holdings: Genetron is a Chinese precision oncology company offering NGS-based cancer panels and liquid biopsy services. It is an emerging peer to CapitalBiotech in the oncology targeted-therapy guidance segment, particularly for lung and colorectal cancer panels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds5 records

Investors34 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CapitalBio Technology